Incyte CORP

Incyte announced robust second quarter 2026 financial results, driven by broad-based sales growth across its portfolio, and raised its full-year financial guidance.

Incyte has finalized its acquisition of Vega Therapeutics, adding the investigational VWD therapy VGA039 to its hematology portfolio.

Incyte Corporation held its Annual Meeting of Shareholders on June 8, 2026, where directors were elected, executive compensation was approved, and the independent auditor was ratified.

Incyte Corporation announced a definitive agreement to acquire Vega Therapeutics, Inc. for $1.25 billion, aiming to expand its hematology portfolio with the investigational antibody VGA039.

Incyte announces robust Q1 2026 financial results with a 20% increase in net sales, driven by key products like Jakafi and Opzelura, alongside significant progress in its late-stage pipeline and anticipated product approvals.

Incyte Corporation announced key executive leadership appointments and title changes to enhance strategic focus and long-term growth plans, effective immediately.

Incyte Corporation announced significant revenue growth and net income for the second quarter and first half of 2026, driven by strong performance across its hematology and oncology franchises, particularly JAKAFI and OPZELURA.

Incyte Corporation announced robust financial results for the first quarter of 2026, with total revenues reaching $1.27 billion, a significant increase driven by strong net sales across its product portfolio, particularly JAKAFI and OPZELURA.

Incyte Corporation delivered robust financial results for Q3 2025, driven by strong product sales and a favorable resolution of a key royalty dispute, significantly boosting net income.

Incyte Corporation achieved significant net income in the second quarter of 2025, driven by robust product revenue increases across its oncology and dermatology portfolios and strategic advancements in its clinical pipeline.

Incyte Corporation announces positive first quarter 2025 financial results, highlighted by increased product revenues and strategic advancements in its pipeline.

Incyte's Q3 2024 results show a net income of $106.5 million, a decrease compared to the previous year, alongside significant strategic moves including a pipeline review and acquisition integration.

Incyte Corporation reported a significant surge in net income and total revenues for 2025, driven by robust product sales and key clinical advancements, despite looming patent expirations for its flagship drug.

Incyte reports increased revenue driven by JAKAFI and OPZELURA, alongside strategic pipeline adjustments and a significant share repurchase program in its 2024 annual report.

Incyte Corporation filed an amendment to its annual report on Form 10-K to correct an administrative error related to the company's policy for recoupment of erroneously awarded compensation.

Incyte Corporation's 2023 annual report reveals a strong financial performance, driven by increased product sales and strategic collaborations.

Pablo J Cagnoni, President, Global Head of R&D of Incyte Corp, sold 10,803 shares of common stock on August 12, 2026 for $120.04 per share.

Pablo J Cagnoni, President, Global Head of R&D of Incyte Corp, sold 10,640 shares of common stock on August 5, 2026 for $122.69 per share.

Michael James Morrissey, EVP, Head of Tech. Operations of Incyte Corp, reported multiple transactions in common stock on July 23, 2026.

Lee Heeson, EVP, Head of Incyte Intl of Incyte Corp, reported multiple transactions in common stock on July 23, 2026.

Thomas Tray, Principal Accounting Officer of Incyte Corp, reported multiple transactions in common stock on July 16, 2026.

Steven H Stein, CMO & Head of Late-Stage Dev. of Incyte Corp, sold 1,877 shares of common stock on July 16, 2026 for $114.73 per share.

Incyte Corporation announces its 2026 Annual Meeting of Shareholders, detailing director elections, executive compensation, and auditor ratification, alongside a strong 2025 performance review.

Incyte Corporation will hold its annual stockholder meeting on June 10, 2025, to vote on director elections, executive compensation, stock incentive plans, and the ratification of its public accounting firm.

Incyte's total revenues grew by 15% in 2024, reaching $4.2 billion, driven by Jakafi and Opzelura, with significant pipeline advancements setting the stage for a pivotal 2025.

Incyte Corporation releases a supplement to its proxy statement, clarifying details regarding the make-whole equity award granted to Dr. Pablo J. Cagnoni, President of Research and Development.

Incyte Corporation announces its annual stockholder meeting to be held on June 12, 2024, outlining proposals for director elections, executive compensation approval, and auditor ratification.

Incyte's product and royalty revenues grew 14% to $3.7 billion in 2023, driven by Opzelura and Jakafi, with significant progress in regulatory and clinical milestones.

Baker Bros. Advisors LP and affiliated entities have updated their Schedule 13D filing concerning their beneficial ownership of Incyte Corporation common stock, reflecting recent option exercises and loan arrangements.

Baker Bros. Advisors and affiliated funds have entered into a registration rights agreement with Incyte Corp, allowing for future resale of their significant stake.

Dodge & Cox has reported a beneficial ownership of 12,252,356 shares, representing 6.2% of Incyte Corporation's common stock, as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 12,591,630 shares, representing 6.32% of Incyte Corp's common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for Incyte Corp, reporting zero beneficial ownership following an internal realignment that disaggregated reporting.

State Street Corporation has reported a 5% beneficial ownership stake in Incyte Corp's common stock as of September 30, 2025.

Incyte Corporation has reported a 9.9% beneficial ownership stake in Prelude Therapeutics, Inc., holding 4,372,124 shares of common stock.

BlackRock, Inc. has reported an increased beneficial ownership of 7.8% in Incyte Corporation's common stock as of September 30, 2025.